Q4 2025 Earnings Estimate for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Issued By Zacks Research

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Equities research analysts at Zacks Research increased their Q4 2025 EPS estimates for Jazz Pharmaceuticals in a note issued to investors on Monday, October 14th. Zacks Research analyst S. Ganoria now anticipates that the specialty pharmaceutical company will post earnings per share of $4.55 for the quarter, up from their previous estimate of $4.53. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.03 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ FY2026 earnings at $17.70 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion.

A number of other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Wells Fargo & Company cut their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. Morgan Stanley lowered their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Friday, July 12th. Finally, HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $173.14.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $115.65 on Wednesday. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. The firm has a market cap of $7.29 billion, a P/E ratio of 23.85, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. The stock’s 50-day moving average is $110.78 and its two-hundred day moving average is $109.78. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $137.38.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several large investors have recently bought and sold shares of JAZZ. EverSource Wealth Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Jazz Pharmaceuticals by 0.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock valued at $1,937,000 after acquiring an additional 99 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 1.4% during the 1st quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock valued at $896,000 after acquiring an additional 105 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 116 shares during the last quarter. Finally, Platinum Investment Management Ltd. raised its position in shares of Jazz Pharmaceuticals by 17.8% during the 1st quarter. Platinum Investment Management Ltd. now owns 821 shares of the specialty pharmaceutical company’s stock valued at $99,000 after acquiring an additional 124 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.